Blue Star Board Approves Unaudited Financial Results for Q2 & H1 2026

Blue Star Limited has announced the Board’s approval of the unaudited standalone and consolidated financial results for the second quarter (Q2: Jul-Sep) and first half (H1: Apr-Sep) of fiscal year 2026, during its meeting held on November 5, 2025. The financial results are available on the company website. Key figures, including revenue and profit, indicate performance for the quarter and half-year periods ending on September 30, 2025.

Financial Performance Overview

The Board of Directors of Blue Star Limited convened on November 5, 2025, to review and approve the unaudited financial results for both the second quarter and the first half of the fiscal year 2026. The results, which cover the period ending September 30, 2025, are now accessible on the company’s official website.

Consolidated Results Highlights

Blue Star Limited reported the following key consolidated figures:

  • Revenue from operations: ₹2,422.37 Crores for the quarter and ₹5,404.62 Crores for the half year.
  • Total Income: ₹2,432.38 Crores for the quarter and ₹5,430.70 Crores for the half year.
  • Profit Before Tax: ₹132.17 Crores for the quarter and ₹295.40 Crores for the half year.
  • Profit After Tax: ₹98.78 Crores for the quarter and ₹219.60 Crores for the half year.

Segment Performance

Key highlights from different segments include:

  • Electro-mechanical projects and commercial air conditioning systems: Revenue of ₹1,664.21 Crores for the quarter.
  • Unitary products: Revenue of ₹693.81 Crores for the quarter.
  • Professional electronics and industrial systems: Revenue of ₹64.35 Crores for the quarter.

Standalone Results Highlights

Key standalone figures reported by Blue Star Limited:

  • Revenue from operations: ₹2,294.52 Crores for the quarter.
  • Profit Before Tax: ₹94.46 Crores for the quarter.
  • Profit After Tax: ₹69.91 Crores for the quarter.

Source: BSE

Previous Article

MapmyIndia Secures National Geo-Spatial Platform Project from Survey of India

Next Article

Sun Pharma Reports Strong Q2FY26 Performance; Approves MoA Alteration

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *